|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase IV
|
|
|
|
Supportive care, Treatment
|
|
|
|
Active
|
|
|
|
18 to 75
|
|
|
|
NIMH
|
|
|
|
R01 MH071580 DATR A3-NSS, NCT00352885
|
|
|
|
|
|
|
|
Last Modified: 2/13/2007  First Published: 1/1/1996 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
75 and under
|
|
|
|
Other
|
|
|
|
CNR-9506 EU-95024, NCT00002702
|
|
|
|
|
|
|
|
Last Modified: 6/11/2008  First Published: 6/1/1999 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
NCI, Pharmaceutical / Industry
|
|
|
|
CCCGHS-NCI-T98-0085 NCI-T98-0085, NCI-99-C-0051B, T98-0085, NCT00019682
|
|
|
|
|
|
|
|
Last Modified: 7/3/2008  First Published: 11/1/1999 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
15 to 60
|
|
|
|
Other
|
|
|
|
EORTC-06991 NCT00004128, GIMEMA-EORTC-06991
|
|
|
|
|
|
|
|
Last Modified: 10/11/2008  First Published: 11/1/2001 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
30 and under at diagnosis
|
|
|
|
NCI
|
|
|
|
COG-ANBL0032 COG-P9842, NCT00026312
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
Under 75
|
|
|
|
Other
|
|
|
|
BRD/04/1-D NCT00200577
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase III
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
Not specified
|
|
|
|
Other
|
|
|
|
A/100/0402 NCT00477906
|
|
|
|
|
|
|
|
Last Modified: 8/23/2008  First Published: 12/1/2001 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II, Phase I
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
18 and over
|
|
|
|
NCI, Other
|
|
|
|
WSU-2006-130 NCT00027807, RWMC-0635146, WSU-010307M1F, WSU-0312004412
|
|
|
|
|
|
|
|
Last Modified: 4/29/2008  First Published: 11/24/2002 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II, Phase I
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
75 and under
|
|
|
|
NCI
|
|
|
|
FHCRC-1655.00 NCT00052520
|
|
|
|
|
|
|
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II, Phase I
|
|
|
|
Treatment
|
|
|
|
Active
|
|
|
|
20 to 75
|
|
|
|
Other
|
|
|
|
27MD02 NCT00154713
|
|
|
|